TOP HEADLINES

Featured Story

Quest scientists and others identify new rheumatoid arthritis biomarker

Researchers have identified a new biomarker for rheumatoid arthritis that could help with earlier diagnosis and treatment.

Corgenix agrees to sell itself to German specialty Dx rival

Corgenix, in the news recently for its Ebola virus test, will sell itself to a competitor based in Germany for about $16 million. The news comes 5 months after the Denver company revealed it might seek to become an M&A target, in part, to reduce costs and boost efficiency and market reach.

Roche's Ventana expands infrastructure in Arizona

Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.

FDA signs off on highly specific Type 1 diabetes biomarker test

The FDA has signed off on a new, highly specific biomarker blood test designed by an Idaho company to quickly spot Type 1 diabetes.

Flagship Biosciences and Sarepta will automate muscular dystrophy biomarker detection

Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.

MORE NEWS

From Our Sister Sites

FierceBiotech

Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.

FierceCRO

German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.